Post Profile






A biotech company erased $3 billion in value overnight after one of its drugs failed a key trial (ALNY)

Biotech company Alnylam Pharmaceuticals is down almost 50% Thursday after stopping a late-stage clinical trial. The drug, revusiran, was being developed to treat a condition called hereditary ATTR amyloidosis with cardiomyopathy. It's a rare disease in which amyloid proteins build up in the body, in particular the heart. Alnylam discontinued the trial after 18 patients died who were part of the trial.
read more

share

Related Posts


Alnylam Pharmaceuticals, Inc. (ALNY)’s Surge Caps Off a Strong Week in Biotech

Business & Finance / Investing : Insider Monkey

Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts. Even the Nasdaq Biotechnology Index can swing wildl...

ACADIA Pharmaceuticals Inc. (ACAD), Alnylam Pharmaceuticals, Inc. (ALNY) & Celldex Therapeutics, Inc. (CLDX): Buy These Biotech Companies for Long-Term Growth

Business & Finance / Investing : Insider Monkey

According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year. This growth is due to rising research and development of new drugs, along with well-established pro...

Biotech stock crashes 70% after a failed drug trial (EBIO, IBB)

Business & Finance : Business Insider: Clusterstock

Shares of Eleven Biotherapeutics fell to nearly zero on Monday after the company announced failed test results on a key drug. In a statement Monday, the company said its lead drug candidate failed a Phase 3 study to treat moderate t...

Inovio Pharmaceuticals Inc (INO), Alnylam Pharmaceuticals, Inc. (ALNY): This Company Is in a Perfect Position to Take-off

Business & Finance / Investing : Insider Monkey

In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole. Now, this speculative growth market is so sensitive that even positive results from clinical trials can take a comp...

Pipeline Probe: Alnylam Pharmaceuticals, Inc. (ALNY)

Business & Finance / Investing : Insider Monkey

Shares of biotech Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have soared over 160% in the past year. The company’s a leader in developing drugs and delivery systems centered on RNA interference, or RNAi, It’s an emerging area that ...

Comments


Copyright © 2016 Regator, LLC